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Ameloblastoma of the Jaws: A
Retrospective Analysis of 340 Cases in a
Malaysian Population
Chong Huat Siar, BDS, MSc, FDSRCPS, FRCPath,*
Shin Hin Lau, BDS, MSc, FDSRCS,† and
Kok Han Ng, BDS, MSc, FDSRCPS, FRCPath‡
Purpose: Ameloblastoma of the human jaw is an uncommon but clinically significant odontogenic
epithelial neoplasm. The aim was to analyze the clinicopathologic characteristics of ameloblastoma in a
Malaysian population.
Materials and Methods: This is a retrospective study (1993 through 2008) of consecutive ameloblas-
toma cases accessioned in 2 main oral pathology diagnostic centers: the Unit of Stomatology, Institute for
Medical Research and the Department of Oral Pathology, Oral Medicine, and Periodontology, Faculty of
Dentistry, University of Malaya, Kuala Lumpur, Malaysia. Data on patient demographics, tumor location,
symptomology, duration, radiographic appearance, preoperative diagnosis, clinicopathologic subtypes,
treatment, and recurrence were analyzed.
Results: Three hundred forty cases of ameloblastoma were reviewed. These were from 197 male patients
(57.9%) and 143 female patients (42.1%), with a male-to-female ratio of 1.4:1. A wide age range (7 to 85 years),
mean onset age of 30.3  16.3 years, and peak incidence in the second decade of life were recorded. Most
were mandibular tumors (n  311/340, 91.5%). These consisted of 95 (28%) unicystic ameloblastomas, 221
(65%) solid/multicystic ameloblastomas, 22 (6.4%) desmoplastic ameloblastoma, and 2 (0.6%) peripheral
ameloblastomas. Unicystic ameloblastoma (41.1%) and solid/multicystic ameloblastoma (52.0%) mostly af-
fected Malays patients, whereas desmoplastic ameloblastoma (59.1%) was prevalent in Chinese patients.
Unicystic ameloblastoma (56.8%) and solid/multicystic ameloblastoma (47.1%) occurred predominantly in the
body and posterior mandible, whereas desmoplastic ameloblastoma (36.4%) preferentially involved the
anterior jaw segment. Most tumors presented as multilocular radiolucencies (36.8%). Enucleation (n 42/92,
45.7%) was the treatment of choice. About 18 cases (13.3%) presented with recurrence.
Conclusions: Because ameloblastoma subsets differ in their biologic behavior, the present data are
significant as baseline references for clinicians and pathologists.
© 2012 American Association of Oral and Maxillofacial Surgeons
J Oral Maxillofac Surg 70:608-615, 2012
0n the recent histologic classification of odontogenic
umors from the World Health Organization (WHO),
meloblastoma is defined as a benign, locally invasive
pithelial odontogenic neoplasm of putative enamel
rgan origin.1,2 It is the second most common odon-
togenic neoplasm and accounts for approximately
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60811% to 18% of all odontogenic tumors. There are 4
distinct clinicopathologic subtypes: unicystic ameloblas-
toma (UA), solid/multicystic ameloblastoma (SMA), and
peripheral and malignant forms.1 SMA and UA form
the 2 major subsets.1,2 SMA has great infiltrative po-
tential and a higher recurrence rate. In contrast, UA
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SIAR, LAU, AND NG 609has an odontogenic cystlike behavior, occurs at a
younger age, and has a lower recurrence rate.
Malaysia, located at the southernmost tip of the
Asian continent, is a multiracial, multicultural nation
with a population of about 28 million. The 3 main
racial groups are the Malays (65.0%), Chinese (26.0%),
and Indians (8.0%). In the Malaysian capital city of
Kuala Lumpur, there are 2 main oral pathology biopsy
diagnostic centers. The Unit of Stomatology at the
Institute for Medical Research was established in 1967
and subserves as the main oral pathology diagnostic
service center for most government-based dental clin-
ics and hospitals in Malaysia. The other diagnostic
center is the Department of Oral Pathology, Oral
Medicine, and Periodontology at the Faculty of Den-
tistry, University of Malaya. This department was
formed when the first dental school in Malaysia was
established in 1972. It offers an oral pathology diag-
nostic service not only for patients accessioned in the
dental school but also for referral cases in the Klang
Valley district. The latter refers to Kuala Lumpur and
its suburbs and the adjoining cities and towns in the
state of Selangor.
Ameloblastoma is a clinically significant tumor in
this region and has been the subject of considerable
studies.3-7 A previous study3 examined 401 ameloblas-
oma cases based on the WHO’s 1971 Histological
yping of Odontogenic Tumours, Jaw Cysts and Al-
ied Lesions.8 However, little is known about amelo-
blastoma and its variants based on the new 2005
World Health Organization Classification of Odon-
togenic Tumours.1
The aim of the present study was to retrospectively
analyze ameloblastoma cases diagnosed in the 2 afore-
mentioned centers from 1993 through 2008, classify
them according to criteria of the 2005 WHO classifi-
cation,1 and determine their clinicopathologic char-
acteristics.
Materials and Methods
The surgical biopsy records of all histologically di-
agnosed cases of ameloblastoma archived from Janu-
ary 1993 through December 2008 inclusive were re-
trieved from the files of the Unit of Stomatology,
Institute for Medical Research and the Department of
Oral Pathology, Oral Medicine, and Periodontology,
Faculty of Dentistry, University of Malaya, Kuala Lum-
pur, Malaysia. This was a retrospective study that was
exempted from institutional review board approval
(research grant RG83/09HTM). A patients’ age, gen-
der, race, location, clinical signs and symptoms, du-
ration, radiographic appearance, preoperative diagno-
sis, treatment, and recurrence were abstracted from
the case summaries accompanying the biopsy speci-
mens. For analysis of mandibular ameloblastomas, siteof occurrence was categorized into anterior (incisal–
canine), body (premolar–molar region), posterior
(distal to third molar), and bilateral (across midline)
regions. For the mandible, the posterior area also
included the ramus, angle, coronoid process, and con-
dyle. For maxillary tumors, site was subdivided into
anterior (incisal–canine) and posterior (distal to ca-
nine) regions. Any tumor involving 2 or more sites
was assigned to the region approximating the center
of the lesion. Any recurrent tumors arising from these
cases were not considered as separate or additional
cases. Sections of all primary and recurrent tumors
stained with hematoxylin and eosin were retrieved
and reviewed to reclassify them according to criteria
of the recent WHO classification of odontogenic tu-
mors.1
Descriptive statistics were performed to calculate
the frequency and percentages of these variables. Age
was stratified into various groups at 10-year intervals.
Statistical analysis was carried out using SPSS 12.0
(SPSS, Inc, Chicago, IL). The Fisher exact test for
differences between 2 groups and the Kruskal-Wallis
test for differences among 3 or more groups were
used as appropriate. The level of statistical signifi-
cance was set at P  .05.
Results
CLINICAL FINDINGS
From the 1,234 cases of odontogenic tumors (exclud-
ing keratocystic odontogenic tumors) accessioned over
the 16-year study period, 340 histologically confirmed
ameloblastomas were analyzed, yielding an incidence
of 27.6%. The distribution of these cases according to
ethnicity, anatomic location, mean duration, radio-
logic appearance, and clinicopathologic subtypes are
presented in Table 1. Statistical analysis showed sig-
nificant differences in the distribution of ameloblas-
toma in relation to ethnicity and anatomic location
(P  .05).
Clinical information was available in 135 cases
(100%). Mean duration of clinical symptoms was 13.6
months (range, 4 days to 15 years). A slowly enlarg-
ing, painless swelling (n  99, 73.3%) was the most
ommon presenting complaint. Numbness (n  7,
.2%), soft tissue growth (n  6, 4.4%), discharging
inus (n  4, 3.0%), and a nonhealing extraction
ocket (n  1, 0.7%) were uncommon. Only 1 case
as asymptomatic.
RADIOLOGIC FINDINGS
A multilocular radiolucency was the most fre-
quently encountered radiographic appearance (Table
1). Sixteen cases (6.7%) presented with root resorp-
tion and 8 (3.4%) were associated with unerupted
teeth.
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610 AMELOBLASTOMA OF THE JAWSPREOPERATIVE DIAGNOSIS
There were 130 cases (100%) with known preop-
erative diagnoses. An ameloblastoma (n  103,
79.2%) was the most common diagnosis, followed by
dentigerous cyst (n  8, 6.2%) and odontogenic ker-
atocyst (n  6 cases, 4.6%).
PATHOLOGIC FINDINGS
Four clinicopathologic subtypes of ameloblastoma
were identified: UA (n  95, 27.9%), SMA (n  221,
65%), desmoplastic ameloblastoma (DA; n  22,
6.4%), and peripheral ameloblastoma (PA; n  2,
.6%). Details of their distribution according to age,
thnicity, and anatomic location are shown in Figures
-3. Mean onset ages of UA, SMA, and DA were sig-
ificantly different (P  .05). All subtypes showed a
ale predominance except for UA and SMA, which
howed a slight preponderance in Chinese and ethnic
inority females, respectively. UA and SMA preferen-
ially affected the body (n  90) and posterior man-
ible (n  68), whereas DA exhibited a predilection
or the anterior jaw segment (n  8). In SMA, the 2
most common histologic growth patterns encoun-
tered were plexiform (n  104) and follicular (n 
0). Granular cell (n  11), acanthomatous (n  9),
Table 1. SUMMARY OF DATA ON 340 CASES OF AMEL
M
otal number of cases (n  340) 197 (
Age (yr), mean (range) 31.9 (
Ethnicity (n  340, 100%)
Malay (n  162, 47.6%) 101 (
Chinese (n  118, 34.8%) 59 (
Indians (n  24, 7.0%) 18 (
Others (n  36, 10.6%) 20 (
Anatomic location (n  340, 100%)
Mandible (n  311, 91.5%) 179 (
Maxilla (n  29, 8.5%) 18 (
Known duration, mean (range) 13.7 mo (
Radiologic appearance (n  239, 100%)
MLRL (n  88, 36.8%) 54 (
ULRL (n  48, 20.1%) 26 (
RLNOS (n  33, 13.8%) 17 (
Mixed RL-RO (n  7, 2.9%) 5 (
RO (n  1, 0.4%) 1 (
Others (n  62, 26.0%) 38 (
Ameloblastoma subtypes (n  340,
100%)
Solid/multicystic (n  221, 65.0%) 130 (
Unicystic (n  95, 28.0%) 54 (
Desmoplastic (n  22, 6.4%) 13 (
Peripheral (n  2, 0.6%) 1 (
Abbreviations: ML, multilocular; NOS, not otherwise specifi
Siar, Lau, and Ng. Ameloblastoma of the Jaws. J Oral Maxillofacnd basaloid (n  1) variants were rare. aTREATMENT AND FOLLOW-UP
Information on primary treatment was known in 92
cases (100%). Most were treated conservatively by
enucleation and/or curettage (n  42, 45.7%), local
excision (n 27, 29.4%), or marginal resection (n 11,
12.0%). Segmental resection (n  4, 4.3%), hemimaxil-
lectomy (n  4, 4.3%), hemimandibulectomy (n  3,
3.2%), and decompression (n 1, 1.1%) were the other
treatment methods recorded.
Follow-up information was available in 135 cases
(100%). Eighteen cases (13.3%) presented with recur-
rence (mean onset age, 7.3 years; range, 1 to 29
years). Patients’ data are presented in Table 2. Of
these, 3 cases had multiple recurrences. Twenty-three
(100%) recurrent tumors consisting of 6 UAs (26.1%)
and 17 SMAs (73.9%) were recorded.
Discussion
In the present study, all 340 cases were classified
according to the new 2005 WHO classification.1 A
search of the English-language literature disclosed few
reports that reviewed large series of ameloblastomas
per se9-12 or odontogenic tumors13-16 in accordance
with the new 2005 WHO classification.1 Recent
STOMA
Female Male:Female
) 143 (42.1%) 1.4:1
28.3 (7–85) —
) 61 (17.9%) 1.7:1
) 59 (17.4%) 1:1
6 (1.7%) 3:1
16 (4.7%) 1.2:1
) 132 (38.8%) 1.4:1
11 (3.2%) 1.6:1
15 yr) 13.5 mo (4 days–10 yr)
) 34 (14.2%) 1.6:1
) 22 (9.2%) 1.2:1
16 (6.7%) 1.1:1
2 (0.8%) 2.5:1
0 (0) —
) 24 (10.0%) 1.6:1
) 91 (26.8%) 1.4:1
) 41 (12.1%) 1.3:1
9 (2.6%) 1.4:1
1 (0.3%) 1:1
, radiolucency; RO, radiopacity; UL, unilocular.
012.OBLA
ale
57.9%
8–84)
29.7%
17.4%
5.3%)
5.9%)
52.6%
5.3%)
1 wk–
22.6%
10.9%
7.1%)
2.1%)
0.4%)
16.0%
38.2%
15.9%
3.8%)
0.3%)
ed; RLmeloblastoma review series have included a multi-
SIAR, LAU, AND NG 611FIGURE 1. Age distribution of ameloblastoma subtypes. DA, desmoplastic ameloblastoma; PA, peripheral ameloblastoma; SMA, solid/
multicystic ameloblastoma; UA, unicystic ameloblastoma.Siar, Lau, and Ng. Ameloblastoma of the Jaws. J Oral Maxillofac Surg 2012.FIGURE 2. Ethnic distribution of ameloblastoma subtypes. CF, Chinese female; CM, Chinese male; DA, desmoplastic ameloblastoma; IF,
Indian female; IM, Indian male; MF, Malay female; MM, Malay male; OF, other females; OM, other males; SMA, solid/multicystic
ameloblastoma; UA, unicystic ameloblastoma.Siar, Lau, and Ng. Ameloblastoma of the Jaws. J Oral Maxillofac Surg 2012.
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612 AMELOBLASTOMA OF THE JAWScentric Latin-American study on 163 cases of amelo-
blastoma,9 a critical appraisal of 25 cases from a single
institution,10 a comparative analysis of mandibular
251 cases) versus maxillary (31 cases) ameloblasto-
as in Sri Lanka,11 and a prevalence study of 37 cases
in Chinese children and adolescents.12 For odonto-
enic tumor series based on the 2005 WHO classifi-
ation, these have included a retrospective study of
,642 cases (inclusive of 661 ameloblastomas) in a
hinese population,13 an analysis of 238 odontogenic
tumors (inclusive of 57 ameloblastomas) in Brazil,14 a
review of 1,309 cases of odontogenic tumors (inclu-
sive of 478 ameloblastomas) in a northern Chinese
population,15 and a prevalence study of 82 odonto-
enic tumors (inclusive of 34 ameloblastomas) in
gypt.16 From these published reports, certain simi-
larities and differences compared with the present
data were identified.
It is well-known that the demographic profile of
ameloblastoma exhibits considerable geographic vari-
ation, and this has been extensively discussed in a
meta-analysis2 and in other published series.9-23 By
limiting the present comparison with those studies
based on the 2005 WHO classification, the Malaysian
ameloblastomas were found to correlate well with
other Asian and, to a lesser extent, Egyptian amelo-
blastomas in showing a high relative frequency,13,15,16
a wide age distribution,13,15,16 a peak incidence in the
econd decade of life,11,13,15 and slight male predom-
FIGURE 3. Site distribution of A, UA and B, SMA subtypes. DA,
otherwise specified; SMA, solid/multicystic ameloblastoma; UA, u
Siar, Lau, and Ng. Ameloblastoma of the Jaws. J Oral Maxillofacnance.13,15,16 In contrast, in Latin American amelo- cblastomas, the tumors occurred at a lower frequency,
exhibited an almost even gender distribution, and a
wide age range.9 The present data concurred with
previous studies in showing that individuals with UA
tended to be younger than those with SMA,1,15
whereas patients with DA belonged to an even older
age group.8,15
It has been suggested that ameloblastomas are
more prevalent in blacks and people of Asian de-
scent.2 In the present study, although a statistically
ignificant difference in the distribution of ameloblas-
oma in relation to ethnicity was observed, this racial
istribution pattern reflected the local racial popula-
ion ratio.3 In contrast, DA occurred predominantly in
hinese (59.1%), even though this ethnic group
ormed 26.0% of the local racial population.3,8 The
eason for this racial predilection is unclear.
It is well recognized that ameloblastomas occur
ore frequently in the mandible than in the maxilla,
nd that these tumors are located predominantly in
he body and posterior mandible.2,9,13-15,17,19 In the
present study, more than 90% of ameloblastomas
were found in the mandible and most of these tumors
were also located in the body and posterior regions.
The observed prevalence of DA for the anterior jaw
segment agrees with other reported data in the liter-
ature.1,4,8,11,15 A Chinese study found that the more
osterior in the mandible an ameloblastoma was lo-
lastic ameloblastoma; Mand, mandible; Max, maxilla; NOS, not
ameloblastoma.
012.desmop
nicysticated, the younger the patient was at diagnosis.15 In
Table 2. CLINICOPATHOLOGIC CHARACTERISTICS OF 18 CASES OF RECURRENT AMELOBLASTOMA
Recurrence Onset* and Treatment
Age/Gender/
Ethnicity Site Duration
Primary
Tumor Primary Treatment First Treatment Second Treatment Third Treatment
10/M/Malay #43—R condyle NA SMA Enucleation 1 yr Hemimandibulectomy — — — —
11/F/Chinese L angle mand NA UA Excision 1 yr Enucleation 3 yr Excision 5 yr Excision
14/M/Chinese L angle mand NA SMA Excision 8 yr Excision — — — —
15/M/Malay L mand NOS NA UA Enucleation 3 yr Hemimandibulectomy — — — —
16/M/Indian L mand NOS NA SMA NA 17 yr Excision — — — —
16/F/Malay L body mand 3 mo SMA Excision 13 yr Excision — — — —
19/F/Chinese R body mand NA SMA Excision 2 yr Excision — — — —
20/F/Chinese R mand NOS 1 yr UA Enucleation 2 yr Enucleation — — — —
22/M/Malay R mand NOS 4 mo SMA Segmental resection 5 yr Excision 7 yr Curettage — —
23/F/Malay Mand NOS NA UA Enucleation 9 yr Excision — — — —
23/F/Malay R post max 4 mo SMA Excision 6 yr Maxillectomy — — — —
25/F/Chinese R mand NOS 2 yr UA Enucleation 3 yr Curettage — — — —
25/F/Chinese L body mand 6 mo UA Enucleation 2 yr Enucleation — — — —
25/M/Malay L mand NOS NA SMA Curettage 7 yr En bloc — — — —
31/F/Chinese L body mand NA SMA Enucleation 3 yr Excision 4 yr Excision 5 yr Excision
32/M/Indian R post max NA SMA Excision 29 yr Excision — — — —
50/M/Indian R body mand NA SMA NA 20 yr Excision — — — —
67/M/Malay L mand NOS 2 mo SMA Enucleation 1 yr Sequestrectomy — — — —
*Onset refers to duration from primary treatment to subsequent recurrence(s).
#43, mandibular right canine (FDI 2-digit notation system); F, female; L, left; M, male; mand, mandible; max, maxilla; NA, not available; NOS, not otherwise specified; post,
posterior; R, right; SMA, solid/multicystic ameloblastoma; UA, unicystic ameloblastoma.
Siar, Lau, and Ng. Ameloblastoma of the Jaws. J Oral Maxillofac Surg 2012.
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614 AMELOBLASTOMA OF THE JAWSthe present study, this relation could not be demon-
strated.
In tumor duration, the mean for the present series
was 13.6 months. This was considerably shorter than
the reported mean of 4.5 years in Latin Americans.9
The difference may be related to the type of diagnos-
tic services available in these centers. Analysis of
clinical signs and symptoms in this study disclosed
that the most common presenting complaint was a
slowly enlarging, painless swelling (73.3%) and this
correlated well with other studies.2,9,13 In contrast, in
razil about 79% of ameloblastoma were asymptom-
tic,14 whereas most ameloblastomas in China13 and
gypt16 reportedly exhibited self-limited growth and
did not produce any clinical symptoms.
A multilocular radiolucency was the most com-
monly encountered radiographic presentation in the
present series (36.8%) and this agreed with other
studies.12,13 Consequently, an ameloblastoma was
lso the most frequent preoperative diagnosis made in
he present and previous studies.12,13
The present distribution pattern of the various
ameloblastoma subtypes was broadly comparable
with most reported series.9,16 As in other studies, PA
and other cellular variants of SMA, namely granular
cell, basal cell, and acanthomatous forms, were
rare.9,12,16 Although clear cell differentiation was de-
cribed in a previous case of PA,4 this cellular change
as not observed in the present tumor series.
SMA is a locally infiltrating neoplasm and the pre-
erred treatment is wide surgical excision.10 In con-
rast, UA has a cystlike behavior, and a more conser-
ative surgical approach is the treatment of choice.9
There are others who recommended that the third
histologic subtype of UA (showing intraluminal and
intramural proliferations) is an aggressive tumor and
therefore should be treated more radically as for
SMA.13 In the present series, most cases were treated
conservatively by enucleation, local excision, or mar-
ginal resection.
Ameloblastoma is an enigmatic tumor with a strong
tendency to recur after treatment.24-28 The recur-
rence rate (13.3%) in the present series was lower
than the reported recurrence rate for ameloblastoma,
which may range from 15.9% to 20.6%.2,9 It is known
that recurrences can take longer than 20 years to
become apparent and, therefore, the eventual recur-
rence rate may be higher.12,29,30 Recurrence in amelo-
lastoma is believed to be the result of several risk
actors, notably tumor subtype,1,2,26 treatment meth-
ods,26 and tumoral behavior.29 Tumors with a follic-
ular, granular, or acanthomatous growth pattern have
a reportedly high likelihood of recurrence, whereas
desmoplastic, plexiform, and unicystic subtypes have
a relatively low recurrence potential.1,2,26 As with
thers,11 a similar observation was made in the pres-nt study in that two thirds of recurrent ameloblas-
oma cases were SMA (n  12/18, 66.7%) and only
ne third were UA (n  6/18, 33.3%). However, most
f these recurrent SMA tumors had a plexiform
rowth pattern (n  8/12), whereas the remaining
xhibited a follicular growth pattern (n  4/12), but
hese numbers were too small for meaningful evalua-
ion of their relative recurrence potential. Further-
ore, we were unable to determine the recurrence
isk in the other histologic growth patterns because
o recurrences were recorded thus far for the acan-
homatous form (n  9), granular form (n  11), PA
n  2), basaloid form (n  1), and DA (n  22). It is
enerally known that there is a significant association
etween treatment and recurrence outcome in amelo-
lastoma.11,25,30 A systematic review on recurrence
elated to treatment modalities of UA found that enu-
leation alone resulted in the highest recurrence rate
30.5%).25 The present study also found that 15 of 18
ameloblastoma cases (83.3%) that presented with re-
currence underwent conservative surgical therapy
(enucleation, excision, or curettage) of the primary
tumors. Postoperative follow-up for ameloblastoma is
of utmost importance because reportedly more than
50% of recurrences occur within 5 years after treat-
ment.2,12,24 This study also demonstrated that 55%
n  10/18) of recurrences occurred within 5 years
fter primary surgery. It is a well-established fact that
he ameloblastoma is a locally invasive neoplasm with
tendency to recur after many years of apparent
ure.1,2,12,25 Two cases in this series presented with
recurrence 20 and 29 years, respectively, after surgi-
cal therapy. These observations reaffirmed the insidi-
ous biological behavior of this neoplasm and re-
emphasized the necessity for long-term follow-up.12
In summary, 340 cases of ameloblastoma in a Ma-
laysian population were reviewed to determine their
clinicopathologic characteristics. Findings showed
that their distribution patterns according to age, gen-
der, and site compared favorably with other reported
series. The data accrued are useful and of significance
as baseline reference to clinicians and pathologists.
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